Nuclear Factor-κB Activation as a Pathological Mechanism of Lipid Metabolism and Atherosclerosis

被引:118
|
作者
Yu, Xiao-Hua [1 ]
Zheng, Xi-Long [2 ]
Tang, Chao-Ke [1 ]
机构
[1] Univ South China, Key Lab Atherosclerol Hunan Prov, Mol Target New Drug Discovery & Cooperat Innovat, Life Sci Res Ctr, Hengyang, Peoples R China
[2] Univ Calgary, Hlth Sci Ctr, Cumming Sch Med, Dept Biochem & Mol Biol,Libin Cardiovasc Inst Alb, Calgary, AB, Canada
来源
关键词
FOAM CELL-FORMATION; HYDROGEN-SULFIDE; INFLAMMATORY MARKERS; NEGATIVE REGULATION; ENDOTHELIAL-CELLS; SIGNALING PATHWAY; EXPRESSION; ALPHA; INHIBITION; ADHESION;
D O I
10.1016/bs.acc.2015.03.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Atherosclerosis is a chronic inflammatory disease of the arterial wall with lipid-laden lesions, involving a complex interaction between multiple different cell types and cytokine networks. Inflammatory responses mark all stages of atherogenesis: from lipid accumulation in the intima to plaque formation and eventual rupture. One of the most important regulators of inflammation is the transcription factor nuclear factor-kappa B (NF-kappa B), which is activated through the canonical and noncanonical pathways in response to various stimuli. NF-kappa B has long been regarded as a proatherogenic factor, because it is implicated in multiple pathological processes during atherogenesis, including foam cell formation, vascular inflammation, proliferation of vascular smooth muscle cells, arterial calcification, and plaque progression. In contrast, inhibition of NF-kappa B signaling has been shown to protect against atherosclerosis. This chapter aims to discuss recent progress on the roles of NF-kappa B in lipid metabolism and atherosclerosis and also to highlight its potential therapeutic benefits.
引用
收藏
页码:1 / 30
页数:30
相关论文
共 50 条
  • [21] Negative regulation of nuclear factor-κB activation and function by glucocorticoids
    Almawi, WY
    Melemedjian, OK
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2002, 28 (02) : 69 - 78
  • [22] Apoptosis caused by chemotherapeutic inhibition of nuclear factor-κB activation
    Biswas, DK
    Martin, KJ
    McAlister, C
    Cruz, AP
    Graner, E
    Dai, SC
    Pardee, AB
    CANCER RESEARCH, 2003, 63 (02) : 290 - 295
  • [23] The central role of nuclear factor-κB in mesangial cell activation
    Massy, ZA
    Guijarro, C
    O'Donnell, MP
    Kim, YK
    Kashtan, CE
    Egido, J
    Kasiske, BL
    Keane, WF
    KIDNEY INTERNATIONAL, 1999, 56 : S76 - S79
  • [24] Oxidative stress interference with the nuclear factor-κB activation pathways
    Schoonbroodt, S
    Piette, J
    BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1075 - 1083
  • [25] Tempol reduces the activation of nuclear factor-κB in acute inflammation
    Cuzzocrea, S
    Pisano, B
    Dugo, L
    Ianaro, A
    Patel, NSA
    Caputi, AP
    Thiemermann, C
    FREE RADICAL RESEARCH, 2004, 38 (08) : 813 - 819
  • [26] Clinicopathological significance of nuclear factor-κB activation in hepatocellular carcinoma
    Yokoo, Hideki
    Yasuda, Jun
    Nakanishi, Kazuaki
    Chuma, Makoto
    Kamiyama, Toshiya
    Todo, Satoru
    Hirohashi, Setsuo
    Sakamoto, Michiie
    HEPATOLOGY RESEARCH, 2011, 41 (03) : 240 - 249
  • [27] Inhibition of nuclear factor-κB activation by 2′,8"-biapigenin
    Woo, Eun-Rhan
    Pokharel, Yuba Raj
    Yang, Jin Won
    Lee, Song Yi
    Kang, Keon Wook
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (05) : 976 - 980
  • [28] The activation of the nuclear factor-κB system in chronic heart failure
    Jankowska, EA
    Czarny, A
    Zaczynska, E
    Banasiak, W
    Anker, S
    Ponikowski, P
    EUROPEAN HEART JOURNAL, 2003, 24 : 488 - 488
  • [29] Tumor necrosis factor-α induced lipolysis in adipocytes is dependent on the activation of Nuclear Factor-κB transcription factor
    Udupi, V
    Basile, R
    Green, A
    OBESITY RESEARCH, 2001, 9 : 144S - 144S
  • [30] Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-α by inhibiting nuclear factor-κB activation
    Posadas, I
    De Rosa, S
    Terencio, MC
    Payá, M
    Alcaraz, MJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2003, 138 (08) : 1571 - 1579